Latest News on PRCT

Financial News Based On Company


Advertisement
Advertisement

PROCEPT BioRobotics® to Participate in the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026

https://www.globenewswire.com/news-release/2026/11/18/3406163/0/en/procept-biorobotics-to-participate-in-the-piper-sandler-38th-annual-healthcare-conference-on-december-2-2026.html
PROCEPT BioRobotics Corporation announced its management will participate in a fireside discussion at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, at 3:30 p.m. ET. The company, which specializes in surgical robotics for urology, will also host in-person meetings. A live webcast and archived recording of the event will be available on the "Investors" section of their website.

PROCEPT BioRobotics Corporation (PRCT) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/PRCT/
PROCEPT BioRobotics Corporation (PRCT) closed at $23.51, up 0.73%, with after-hours trading showing a decrease to $23.00. The company, which specializes in surgical robotics for urology, reported a Q3 FY26 revenue of $98.29M and an earnings loss of $26.52M. Analysts currently have an average price target of $22.75 for PRCT, with a "Hold" recommendation.

PROCEPT BioRobotics (PRCT) Could Be 61% Undervalued After Earnings And Guidance Reaffirmation

https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/procept-biorobotics-prct-could-be-61-undervalued-after-earni
PROCEPT BioRobotics (PRCT) recently released its third-quarter 2026 results, showing revenue growth but continued net losses. Despite this, management reaffirmed its full-year 2026 revenue guidance, leading to positive short-term share price returns. The Simply Wall St Community narrative suggests the stock is significantly undervalued, pointing to a fair value of $60 compared to the current trading price of $23.34, while a DCF model indicates it might be overvalued at $10.17.

PROCEPT BioRobotics (NASDAQ:PRCT) Raised to Hold at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-procept-biorobotics-nasdaq-prct-raised-to-hold-at-wall-street-zen-2026-11-07/
Wall Street Zen has upgraded PROCEPT BioRobotics (NASDAQ:PRCT) from a "sell" to a "hold" rating, aligning with the overall analyst consensus and a target price of $25.25. This upgrade comes despite the company missing analyst expectations in its latest quarterly report, showing a loss of $0.46 per share and revenue of $98.29 million, although revenue did grow 18% year-over-year. Shares opened at $20.62, within a 52-week range of $16.67 to $38.11, and institutional investors have recently adjusted their holdings in the medical technology company.

Procept BioRobotics chief strat/marketing officer sells $92,852 in stock

https://www.investing.com/news/insider-trading-news/procept-biorobotics-chief-stratmarketing-officer-sells-92852-in-stock-93CH-5009417
Pooja Sharma, Chief Strat/Marketing Officer at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 4,710 shares of common stock for $92,852 on November 6, 2026, due to tax withholding obligations. Following the transaction, Ms. Sharma directly holds 106,471 shares, and the company's stock has shown resilience, with InvestingPro analysis suggesting it is undervalued. PROCEPT BioRobotics recently reported third-quarter 2026 revenue of $98.3 million, an 18% increase year-over-year, but missed Wall Street forecasts and posted a wider-than-expected adjusted loss.
Advertisement

Form 144 PROCEPT BioRobotics Corp For: 6 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-procept-biorobotics-corp-for-6-november-93CH-2791236
This article reports on the filing of Form 144 for PROCEPT BioRobotics Corp (PRCT) on November 6, 2026. Form 144 is a notice of the intent to sell restricted securities. The article provides the company's stock symbol and its current price change.

Will Hydros Adoption Change PROCEPT BioRobotics Stock Narrative

https://simplywall.st/stocks/us/healthcare/nasdaq-prct/procept-biorobotics/news/will-hydros-adoption-change-procept-biorobotics-stock-narrat
PROCEPT BioRobotics reported Q3 2026 revenue of US$98.3 million and a net loss of US$26.5 million, with its performance heavily driven by Hydros adoption. The company reiterated its full-year 2026 revenue guidance of US$390 million to US$410 million and aims for positive adjusted EBITDA in Q4 2026. Investors are closely watching whether the company can achieve its profitability targets amid rising losses and ongoing operating expenses.

Form 144 PROCEPT BioRobotics Corp For: 6 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-procept-biorobotics-corp-for-6-november-93CH-4940111
This article announces the filing of Form 144 for PROCEPT BioRobotics Corp (PRCT) on November 6, 2026. Form 144 indicates an intent to sell restricted securities. The brief notice provides the company name and filing date, along with its current stock performance.

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates

https://ca.finance.yahoo.com/news/procept-biorobotics-corporation-prct-reports-234508330.html
PROCEPT BioRobotics Corporation (PRCT) reported a Q3 loss of $0.46 per share, missing the Zacks Consensus Estimate of a $0.39 loss, and revenues of $98.29 million, falling short of estimates by 1.78%. The company's stock has declined 35.9% year-to-date, underperforming the S&P 500. The current Zacks Rank for PRCT is #3 (Hold), indicating that shares are expected to perform in line with the market.

An officer sells 4,710 PROCEPT BioRobotics (PRCT) shares to cover stock-vesting taxes.

https://www.stocktitan.net/sec-filings/PRCT/form-4-procept-bio-robotics-corp-insider-trading-activity-32abc5223942.html
Pooja Sharma, Chief Strat/Marketing Officer at PROCEPT BioRobotics Corp (PRCT), sold 4,710 shares of common stock on November 6, 2026, at $19.714 per share. This sale was conducted via the issuer’s "sell-to-cover" process for tax withholding obligations related to restricted stock units that vested on November 5, 2026. After the transaction, Sharma directly held 106,471 shares, and no Rule 10b5-1 plan was reported.
Advertisement

PROCEPT BioRobotics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62899373/procept-biorobotics-q3-2026-earnings-call-transcript
PROCEPT BioRobotics reported Q3 2026 revenue of $98.3 million, an 18% year-over-year increase, driven by a 22% rise in U.S. procedures and a successful transition to Hydros systems. The company maintains its 2026 revenue guidance of $390-$410 million, anticipating 27% to 33% growth, and expects to achieve positive adjusted EBITDA in Q4 2026. Management also provided a baseline revenue growth projection of approximately 20% for 2027, with ongoing investments in clinical studies and marketing.

PROCEPT BioRobotics 2026: Revenue $98.29M, Net income ($26.52M), EPS ($0.46) — 10-Q Summary

https://www.tradingview.com/news/tradingview:468dcbe2438c5:0-procept-biorobotics-2026-revenue-98-29m-net-income-26-52m-eps-0-46-10-q-summary/
PROCEPT BioRobotics (PRCT) reported a 18% increase in revenue to $98.29 million for 2026, though its net loss widened to $26.52 million and diluted loss per share grew to $0.46. The company's nine-month revenue also rose 19% to $275.9 million, driven by higher sales across its product and service categories, with the U.S. market remaining its primary focus. Investment continues in hospital adoption, system utilization, patient awareness, and R&D for next-generation products.

An 18% revenue rise comes with a wider Q3 loss at PROCEPT BioRobotics (PRCT).

https://www.stocktitan.net/sec-filings/PRCT/10-q-procept-bio-robotics-corp-quarterly-earnings-report-d941d12ea87b.html
PROCEPT BioRobotics (PRCT) reported an 18% increase in third-quarter revenue to $98.3 million and a 19% rise in nine-month revenue to $275.9 million. Despite this revenue growth, the company's net loss widened to $26.5 million for the quarter and $85.0 million for the nine-month period, attributed to increased operating expenses and cash use. The company attributes its gross margin increase partly to tariff refunds and states that existing cash and anticipated revenue are believed to fund operations for at least the next 12 months.

PROCEPT BioRobotics Corporation (PRCT) Misses Q3 EPS by 7c

https://www.streetinsider.com/Earnings/PROCEPT+BioRobotics+Corporation+%28PRCT%29+Misses+Q3+EPS+by+7c/27291003.html
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) reported a Q3 EPS of ($0.46), missing analyst estimates by $0.07. The company also reported revenue of $98.3 million, which was below the consensus estimate of $100.72 million. This earnings miss suggests a weaker financial performance than anticipated by analysts for the quarter.

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/procept-biorobotics-reports-third-quarter-2026-financial-results-and-reaffirms-2026-financial-guidance/2462226
PROCEPT BioRobotics reported unaudited financial results for the third quarter of 2026, showing an 18% increase in total revenue to $98.3 million and a 22% increase in U.S. procedures. The company reaffirmed its full-year 2026 financial guidance, projecting revenue between $390 million and $410 million, driven by continued expansion of its installed base and strong utilization of HYDROS® systems. They also anticipate presenting data from the WATER IV trial in the first half of 2027.
Advertisement

Form 8K Procept Biorobotics Corp For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-procept-biorobotics-corp-for-4-november-93CH-4931779
This article announces that Procept Biorobotics Corp filed a Form 8K on November 4, 2026. The brief notice from Investing.com provides no further details beyond the filing date and company name. It indicates the stock symbol PRCT and shows a slight decrease in its value.

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

https://www.globenewswire.com/news-release/2026/11/04/3395829/0/en/procept-biorobotics-reports-third-quarter-2026-financial-results-and-reaffirms-2026-financial-guidance.html
PROCEPT BioRobotics announced its third-quarter 2026 financial results, reporting an 18% increase in total revenue to $98.3 million and a 22% rise in U.S. procedures. The company reaffirmed its full-year 2026 revenue guidance of $390 million to $410 million and U.S. procedure volume of 54,000-56,000, while continuing to focus on expanding its HYDROS® system installed base and preparing for WATER IV trial data in early 2027.

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

https://www.stocktitan.net/news/PRCT/procept-bio-robotics-reports-third-quarter-2026-financial-results-y391kmahjkwm.html
PROCEPT BioRobotics reported third-quarter 2026 revenue of $98.3 million, an 18% increase year-over-year, and reaffirmed its full-year 2026 financial guidance for revenue between $390 million and $410 million. The company's net loss widened to $26.5 million from $21.4 million in the prior year period, while gross margin improved slightly to 66%. PROCEPT BioRobotics also confirmed its expectations for U.S. procedure volume and adjusted EBITDA loss for the full year.

(PRCT) Movement as an Input in Quant Signal Sets

https://news.stocktradersdaily.com/news_release/40/PRCT_Movement_as_an_Input_in_Quant_Signal_Sets_110326031201_1793693521.html
This article analyzes Procept Biorobotics Corporation (NASDAQ: PRCT) using AI-generated signals, indicating a near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. It outlines three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Short Risk Hedging Strategy. The analysis also highlights an exceptional short setup with a 53.0:1 risk-reward ratio targeting a 15.2% downside.

PROCEPT BioRobotics Corporation Common Stock (PRCT)

https://milkroad.com/assets/prct/
This article provides a detailed overview of PROCEPT BioRobotics Corporation (PRCT) stock, including its key financial metrics, price performance, and significant institutional holdings. As of October 28, 2026, PRCT was trading at $19.95 USD, with a market capitalization of $1.14 billion and annual revenue of $337 million. Notably, Ken Griffin's Citadel Advisors holds a substantial stake in the company, with recent activity showing an increase in ownership.
Advertisement

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

https://uk.finance.yahoo.com/news/procept-biorobotics-corporation-prct-expected-130011137.html
PROCEPT BioRobotics Corporation (PRCT) is expected to report a year-over-year decline in earnings but higher revenues for the quarter ended September 2026. With a positive Zacks Earnings ESP of +9.79% and a Zacks Rank #3, the company is likely to beat consensus EPS estimates. Investors should also consider other factors beyond earnings surprise history, as PRCT has only beaten consensus EPS estimates once in the last four quarters.

PROCEPT BioRobotics (PRCT) Set to Release Quarterly Earnings on Wednesday

https://www.marketbeat.com/instant-alerts/upcoming-procept-biorobotics-prct-set-to-release-quarterly-earnings-on-wednesday-2026-10-28/
PROCEPT BioRobotics (PRCT) is scheduled to release its Q3 2026 earnings on Wednesday, November 4th, with analysts anticipating a loss of $0.3895 per share and revenue of $100.52 million. The company reported a slightly wider loss in the previous quarter, though revenue increased by 19.3% year over year. Analyst sentiment remains cautious with a "Hold" rating, and the CEO recently acquired a significant number of shares.

PROCEPT BioRobotics Corporation Estimates – NASDAQ:PRCT

https://www.tradingview.com/symbols/NASDAQ-PRCT/financials-estimates/
The article provides an overview of financial data and analyst estimates for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.

PROCEPT BioRobotics sets November 4 results date: what it means for PROCEPT BioRobotics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/procept-biorobotics-sets-november-4-results-date-what-it-means-for-procept-biorobotics-stock/70378682
PROCEPT BioRobotics (PRCT) has scheduled its third-quarter 2026 earnings report for November 4, 2026, after market close, with a conference call at 4:30 p.m. Eastern Time. The company's second-quarter revenue grew by 19.30% year-over-year to USD 94.50 million, though net loss widened. Investors will monitor the upcoming report to assess continued revenue growth and efforts to control losses, especially as the company reaffirmed its full-year 2026 revenue guidance.

PROCEPT BioRobotics sets November 4 results date: what it means for PROCEPT BioRobotics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/procept-biorobotics-sets-november-4-results-date-what-it-means-for/70334111
PROCEPT BioRobotics (PRCT) has scheduled its third-quarter 2026 results for November 4, 2026, with a conference call set for 4:30 p.m. ET on the same day. This announcement follows a second quarter where the company reported revenue of USD 94.50 million, a 19.30 percent year-over-year increase, but also a GAAP net loss of USD 26.86 million, missing quarterly earnings expectations. Leerink Partners maintained a Hold rating and a USD 20.00 price target for the stock, emphasizing that the upcoming report will test the company's ability to extend growth while addressing profitability concerns.
Advertisement

PRCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PROCEPT BioRobotics Corporation Stockholders Have Opportunity to Lead Class Action Lawsuit!

https://natlawreview.com/press-releases/prct-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-procept-8
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) and its officers. The lawsuit alleges that the company made materially false and misleading statements to investors between February 28, 2024, and February 25, 2026, regarding its business practices, financial condition, and product utilization. Investors who suffered losses are encouraged to join the lawsuit and may request to be appointed lead plaintiff by September 22, 2026.

PROCEPT BioRobotics sets November 4 results date: what it means for PROCEPT BioRobotics stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/procept-biorobotics-sets-november-4-results-date-what-it-means-for-procept-biorobotics-stock/70334111
PROCEPT BioRobotics (PRCT) has scheduled its third-quarter 2026 results for November 4, 2026, with a conference call set for 4:30 p.m. ET on the same day. This announcement follows a second quarter where revenue reached USD 94.50 million, a 19.30% increase year-over-year, alongside a GAAP net loss of USD 26.86 million. Leerink Partners maintained a Hold rating with a USD 20.00 price target, and the upcoming results will be crucial in assessing the company's continued growth and profitability.

PROCEPT BioRobotics Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-4-procept-biorobotics-corp-stock/
PROCEPT BioRobotics (NASDAQ: PRCT) is expected to announce its Q3 2026 earnings on Wednesday, November 4, 2026, after market close, with a conference call scheduled for 4:30 PM ET. Analysts project an EPS of -$0.3895 on revenue of $100.72 million. The company's Aquablation therapy for benign prostatic hyperplasia (BPH) is highlighted as its primary focus.

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

https://sg.finance.yahoo.com/news/procept-biorobotics-report-third-quarter-200500435.html
PROCEPT BioRobotics Corporation announced it will report its third-quarter 2026 financial results after market close on Wednesday, November 4, 2026. The company will host a conference call at 4:30 p.m. Eastern Time for investors, with webcast and dial-in details provided. PROCEPT BioRobotics is a surgical robotics company focused on urology, manufacturing the AQUABEAM® and HYDROS® Robotic Systems for conditions like BPH.

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

https://ca.finance.yahoo.com/news/procept-biorobotics-report-third-quarter-200500435.html
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) announced it will release its third-quarter 2026 financial results after market close on Wednesday, November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Interested investors can access the webcast or dial-in through provided links on the company's investor relations website.
Advertisement

A surgical robotics company will host a results call at 4:30 p.m. ET on Nov. 4.

https://www.stocktitan.net/news/PRCT/procept-bio-robotics-to-report-third-quarter-2026-financial-results-1icxelpnjjon.html
PROCEPT BioRobotics (Nasdaq: PRCT) announced it will report its third-quarter 2026 financial results after market close on November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss these results, with live audio and archived recordings available on the company's investor website. The company specializes in surgical robotics for urology, including the AQUABEAM® and HYDROS® Robotic Systems for treating BPH.

PROCEPT BioRobotics Corporation to Report Third Quarter 2026 Financial Results on November 4, 2026

https://www.quiverquant.com/news/PROCEPT+BioRobotics+Corporation+to+Report+Third+Quarter+2026+Financial+Results+on+November+4%2C+2026
PROCEPT BioRobotics Corporation will report its Q3 2026 financial results on November 4, 2026, after market close, followed by a conference call at 4:30 p.m. ET. The company specializes in surgical robotics for urology, including the AQUABEAM and HYDROS Robotic Systems for BPH treatment and is involved in prostate cancer research. Insider trading activity and institutional holdings data for PRCT are also provided, along with recent analyst price targets.

PROCEPT BioRobotics Corporation to Report Third Quarter 2026 Financial Results on November 4, 2026

https://www.quiverquant.com/news/PROCEPT+BioRobotics+Corporation+to+Report+Third+Quarter+2026+Financial+Results+on+November+4,+2026
PROCEPT BioRobotics Corporation (PRCT) announced it will release its third-quarter 2026 financial results on November 4, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time. The company, known for its AQUABEAM and HYDROS Robotic Systems for urology and BPH treatment, also noted recent insider trading activity, with the CEO purchasing shares and other executives making sales, alongside significant institutional investor movements.

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

https://www.globenewswire.com/news-release/2026/10/12/3379227/0/en/procept-biorobotics-to-report-third-quarter-2026-financial-results-on-november-4th-2026.html
PROCEPT BioRobotics Corporation announced it will report its third-quarter 2026 financial results after market close on Wednesday, November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time, with webcast and dial-in options available for investors and analysts. The company, a surgical robotics firm, focuses on urological solutions, manufacturing the AQUABEAM® and HYDROS® Robotic Systems for BPH treatment and exploring applications in prostate cancer.

Form 4 Procept Biorobotics Corp For: 12 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-4-procept-biorobotics-corp-for-12-october-93CH-2731667
This article announces the filing of a Form 4 for Procept Biorobotics Corp on October 12, 2026. Form 4s are filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article indicates that Procept Biorobotics Corp's stock symbol is PRCT, which was up 6.36% at the time of publication.
Advertisement

Form 4 Procept Biorobotics Corp For: 12 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-procept-biorobotics-corp-for-12-october-93CH-4905475
This article announces the filing of Form 4 by Procept Biorobotics Corp on October 12. Form 4 is a U.S. Securities and Exchange Commission document that must be filed by company insiders, such as officers, directors, or beneficial owners, whenever they trade stock in their own company. The filing indicates insider transactions for Procept Biorobotics Corp (PRCT).

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Semtech Corporation (SMTC), Roblox Corporation (RBLX), Quantum Corporation (QMCO), and PROCEPT BioRobotics Corporation (PRCT)

https://supplychaindigital.com/globenewswire/3378240
Johnson Fistel, PLLP is investigating potential claims of fiduciary duty breaches against officers and directors of Semtech Corporation (SMTC), Roblox Corporation (RBLX), Quantum Corporation (QMCO), and PROCEPT BioRobotics Corporation (PRCT). The firm is seeking long-term shareholders who held shares continuously since specific dates to pursue corporate governance reforms and financial restitution for the companies. These investigations stem from previously filed securities class action complaints alleging misleading statements and failures to disclose material adverse facts by these corporations.

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Semtech Corporation (SMTC), Roblox Corporation (RBLX), Quantum Corporation (QMCO), and PROCEPT BioRobotics Corporation (PRCT)

https://www.globenewswire.com/news-release/2026/10/09/3378240/0/en/johnson-fistel-pllp-investigates-claims-on-behalf-of-long-term-shareholders-of-semtech-corporation-smtc-roblox-corporation-rblx-quantum-corporation-qmco-and-procept-biorobotics-cor.html
Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Semtech Corporation (SMTC), Roblox Corporation (RBLX), Quantum Corporation (QMCO), and PROCEPT BioRobotics Corporation (PRCT). The investigations are on behalf of long-term shareholders who have continuously held shares since specific dates. The firm is seeking corporate governance reforms and return of funds, offering representation on a contingency-fee basis.

PROCEPT BioRobotics (NASDAQ:PRCT) Upgraded at Barclays

https://www.marketbeat.com/instant-alerts/analyst-procept-biorobotics-nasdaq-prct-upgraded-at-barclays-2026-10-09/
Barclays has upgraded PROCEPT BioRobotics (NASDAQ:PRCT) to a "strong-buy" rating, despite a broader analyst consensus of "hold" and a mixed bag of recent ratings and price target adjustments from other firms. The company reported 19.3% year-over-year revenue growth but missed EPS estimates and remains unprofitable. Notably, CEO Larry Wood recently purchased nearly $498,000 worth of company stock, while institutional ownership stands at 89.46%.

Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Target

https://www.marketscreener.com/news/barclays-initiates-procept-biorobotics-at-overweight-with-30-price-target-ce785dded88af325
Barclays has initiated coverage on PROCEPT BioRobotics (PRCT) with an "Overweight" rating and a price target of $30. This announcement highlights analyst confidence in the surgical robotics company, which specializes in transformative solutions for urology, particularly with its AquaBeam Robotic System for benign prostatic hyperplasia (BPH). The company's stock has seen fluctuations, with recent earnings reports and other analyst adjustments impacting its market performance.
Advertisement

PROCEPT BioRobotics Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-3-procept-biorobotics-corp-stock/
PROCEPT BioRobotics (PRCT) is projected to release its Q3 2026 earnings on Tuesday, November 3, 2026, after market close, with a conference call scheduled for November 4, 2026. Analysts anticipate an EPS of -$0.3895 on revenues of $100.72 million, marking a 20.9% increase from the prior year. The company's Aquablation therapy and AquaBeam Robotic System are highlighted as key offerings in urologic procedures.

Procept BioRobotics Corp Share Price - PRCT, RNS News, Articles, Quotes, & Charts (NASDAQ:PRCT)

https://www.proactiveinvestors.com/companies/21165/Procept-BioRobotics-Corp
This article provides financial information for Procept BioRobotics Corp (NASDAQ:PRCT), including its share price, market capitalization, and 52-week high and low. It also highlights the company's Aquablation therapy solution, emphasizing its use of medical expertise and technological innovation for men's health. The page compiles various news headlines and insights relevant to the broader market and specific sectors.

PROCEPT BioRobotics stock gains 3.92 percent as lawsuit risk lingers

https://www.ad-hoc-news.de/boerse/news/corporate-news/procept-biorobotics-stock-gains-3-92-percent-as-lawsuit-risk-lingers/70236819
PROCEPT BioRobotics stock rose by 3.92% despite an ongoing securities lawsuit filed on October 1st, alleging deceptive discounting practices that led to excess handpiece inventory. The company reported Q2 2026 revenue of $94.5 million, exceeding estimates, but an adjusted loss of $0.47 per share, slightly missing analyst expectations. The lawsuit adds legal scrutiny to the company's growth model, even as its stock remains near its yearly low.

A director receives rights to 7,727 shares and options on 12,191 at PROCEPT BioRobotics (PRCT).

https://www.stocktitan.net/sec-filings/PRCT/form-4-procept-bio-robotics-corp-insider-trading-activity-2aea13208c3e.html
PROCEPT BioRobotics director Michael Mack was granted 7,727 restricted stock units (RSUs) and options for 12,191 shares of common stock on October 2, 2026. These awards are subject to a vesting schedule, with one-third vesting on October 2, 2027, and the remainder vesting annually over the subsequent two years, contingent on his continued service. The stock option has an exercise price of $17.16 per share and expires on October 1, 2036.

PROCEPT BioRobotics Corporation Announces Appointment of Dr. Michael Mack as Member of the Board, Effective October 2, 2026

https://www.marketscreener.com/news/procept-biorobotics-corporation-announces-appointment-of-dr-michael-mack-as-member-of-the-board-ef-ce785ddbdd88ff24
PROCEPT BioRobotics Corporation has announced the appointment of Dr. Michael Mack to its Board of Directors, effective October 2, 2026. Dr. Mack, a distinguished cardiac surgeon with extensive leadership experience and over 1,100 peer-reviewed publications, will serve as a Class II independent director until the company's 2029 annual meeting. This strategic addition aims to strengthen the board with Dr. Mack's medical expertise and leadership in healthcare.
Advertisement

Lawsuit filed against PROCEPT BioRobotics over alleged misleading sales practices and financial risks.

https://pluang.com/en/news-feed/tuntutan-hukum-procept-biorobotics-dan-dampaknya-pasar-saham
A lawsuit has been filed against PROCEPT BioRobotics Corporation, alleging that the company misled investors by failing to disclose a discount program that artificially inflated U.S. handpiece sales, leading to overstocking and undisclosed financial risks. The complaint, filed on July 24, 2026, claims that PROCEPT's public statements were false or misleading, and investors who purchased shares are advised to contact the Shareholders Foundation regarding the securities class action lawsuit.

PROCEPT BioRobotics (NASDAQ: PRCT) Investors: Securities Class Action Filed; Shareholders Should Contact Shareholders Foundation

https://www.prnewswire.com/news-releases/procept-biorobotics-nasdaq-prct-investors-securities-class-action-filed-shareholders-should-contact-shareholders-foundation-302895650.html
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) on behalf of investors. The lawsuit alleges that the company misrepresented its business practices by using a discount program to inflate reported U.S. handpiece unit sales, leading to overstocking and undisclosed operational and financial risks. Shareholders who purchased PRCT shares are encouraged to contact the Shareholders Foundation for more information.

LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation

https://www.globenewswire.com/news-release/2026/09/30/3372358/0/en/lawsuit-alert-investors-who-lost-money-with-procept-biorobotics-corporation-nasdaq-prct-shares-should-contact-the-shareholders-foundation.html
A lawsuit has been filed against PROCEPT BioRobotics Corporation (NASDAQ: PRCT) by investors alleging securities law violations. The lawsuit claims that the company misrepresented its U.S. handpiece unit sales through an undisclosed discount program that artificially inflated figures and led to overstocking. Investors who purchased PRCT shares are encouraged to contact the Shareholders Foundation.

Bank of America Corp DE Purchases 516,198 Shares of PROCEPT BioRobotics Corporation $PRCT

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-516198-shares-of-procept-biorobotics-corporation-prct-2026-09-26/
Bank of America Corp DE recently acquired 516,198 shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, valued at approximately $11.7 million, representing 0.9% of the company. Institutional investors and hedge funds own a significant 89.46% of PRCT, while insiders, including CEO Larry Wood who purchased 23,900 shares, hold about 4%. Despite a consensus "Hold" rating from analysts and a price target of $25.09, PRCT opened at $17.20 after reporting a 19.3% increase in quarterly revenue but a larger-than-expected loss per share.

PROCEPT BioRobotics Corporation (PRCT) options chain – Yahoo Finance

https://sg.finance.yahoo.com/quote/PRCT/options/?date=1807833600&straddle=true
This article provides an options chain for PROCEPT BioRobotics Corporation (PRCT), detailing call and put options with various strike prices, last prices, changes, volumes, and open interest. The data includes options expiring on April 16, 2027. The stock PRCT was trading at 17.25 with a slight gain at market close.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement